Background
An estimated 2.4M people in the U.S. live with chronic Hepatitis C (HCV), yet only one third know their status. With rising incidence and many patients disengaged from care, emergency departments (EDs) are key for screening and linkage. However, standard lab based HCV RNA testing delays results beyond the ED visit, leading to loss to follow up. We evaluated the impact of point of care (POC) HCV RNA testing in the ED on timely diagnosis and linkage.
Methods
On Dec 18, 2024, we implemented the Cepheid Xpert HCV Viral Load (POC) test by fingerstick as confirmatory testing. Challenges with capillary collection, workflow disruption, and patient dissatisfaction led to high failure rates. On May 12, 2025, we validated use of venous blood specimens with the Cepheid platform, using blood samples already drawn for care to improve test success and reduce ED workflow impact. Outcomes were assessed across three phases: 1) Standard HCV RNA quantitative (Oct 1–Dec 17, 2024), 2) HCV POC Fingerstick (Dec 18, 2024–May 11, 2025), 3) HCV POC Venous (May 12–Aug 31, 2025).
Results
From Oct 2024–Aug 2025, around 2800 patients were screened monthly with an average of 80 antibody reactive and 20 chronic patients. In the standard phase, turnaround time (TAT) from order to confirmatory result was on average 2,354 minutes, with 0% RNA+ patients still in ED at time of result. In POC fingerstick stage, TAT dropped to 409 minutes with only 20% of RNA+ patients still in ED; on average 1 patient was scheduled monthly. With POC venous, TAT decreased further to 179 minutes on average, with 71% of RNA+ patients still in ED; monthly, an average of 8 patients were scheduled for specialty care before discharge during this phase.
Conclusions
POC HCV RNA testing transitioning from fingerstick to venous blood, reduced confirmatory turnaround from 2,354 to 179 minutes on average and significantly increased opportunities for same-visit linkage. These results support ED-based POC testing as a scalable strategy to reduce loss to follow-up and accelerate entry into care. Expansion across additional ED sites and integration with same-day treatment initiation are next steps.
Table or Figure
